- 28 **Kimura K**, Isashiki Y, Sonoda S, *et al*. Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration. *Am J Ophthalmol* 2000;**130**:769–73.
- 29 **Pritchard JK**, Stephens M, Donnelly P. Inference of population structure from multilocus genotype data. *Genetics* 2000;**155**:945–59.
- 30 **Purcell S**, Cherny SS, Sham PC. Genetic power calculations: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 2003;**19**:149–50.
- 31 **Kinnula VL**, Lehtonen S, Koistinen P, *et al*. Two functional variants of the superoxide dismutase genes in Finnish families with asthma. *Thorax* 2004;**59**:116–9.
- 32 **Bowler RP**, Wheeler C, Duda B, *et al*. Polymorphisms in the extracellular superoxide dismutase gene and plasma EC-SOD concentrations are associated with a decreased risk of COPD. Thomas L Petty Aspen Lung Conference, June, 2005.
- 33 **Juul K**, Tybjaerg-Hansen A, Marklund S, *et al*. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006 (in press).
- 34 **Wilk JB**, Destefano AL, Arnett DK, *et al*. A genome-wide scan of pulmonary function measures in the Heart, Lung and Blood Institute family heart study. *Am J Respir Crit Care Med* 2003;**167**:556–61.
- 35 **Wu L**, Chau J, Young RP, *et al*. Transforming growth factor- β 1 genotype and susceptibility to chronic obstructive pulmonary disease. *Thorax* 2004;**59**:126–9.
- 36 **Ghio AJ**, Suliman HB, Carter JD, *et al*. Overexpression of extracellular superoxide dismutase decreases lung injury after exposure to oil fly ash. *Am J Physiol Lung Cell Mol Physiol* 2002;**283**:L211–8.
- 37 **Hendrik DJ**. Smoking, cadmium and emphysema. *Thorax* 2004;**59**:184–5.
- 38 **Hall IP**, Blakey JD. Genetic association studies in Thorax. *Thorax* 2005;**60**:357–9.

LUNG ALERT

Non-invasive ventilation improves survival in patients with motor neuron disease

▲ Bourke SC, Tomlinson M, Williams TL, *et al*. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. *Lancet Neurol* 2006;**5**:140–7

This randomised controlled trial allocated patients with amyotrophic lateral sclerosis to either standard care (n = 19) or non-invasive ventilation (NIV, n = 22). Patients were randomised when they developed orthopnoea with a maximum inspiratory pressure of <60% or symptomatic daytime hypercapnia. They were assessed with the SF-36 and sleep apnoea quality of life index (SAQLI) scores. The authors found that quality of life scores were maintained at 75% above baseline for longer in the patients randomised to NIV (192 v 46 days, p = 0.0013). Furthermore, in the patients with good bulbar function there was a median survival benefit of 205 days (p = 0.006). The subgroup with poor bulbar function had improved sleep related symptoms but no survival benefit.

This study confirms that, rather than prolonging suffering, NIV extends survival in motor neuron disease with improved quality of life in those with good bulbar function, and improves sleep symptoms in those with poor bulbar function.

A McKendrick

SHO, Kettering General Hospital, UK; avance@doctors.net.uk